Semaglutide
Semaglutide is a GLP-1 receptor agonist peptide that suppresses appetite, increases satiety, and improves glucose metabolism for pharmaceutical-grade weight loss and blood sugar control, achieving average weight loss of 15-18% body weight (30-40+ pounds) over 6 months in individuals with obesity or diabetes through sustained once-weekly injections or oral dosing. FDA-approved for both type 2 diabetes (as Ozempic) and weight management (as Wegovy), it outperforms all prior GLP-1 agonists including liraglutide with superior efficacy and sustained action.
Route
Subcutaneous injection
Dose range
250 mcg – 2.4 mg
Frequency
Once per week (subcutaneous)
Cycle length
Long-term management involves titrating to maintenance

GLP-S 5MG
Third-party tested, lot traceable, ships in 3–5 business days.
Overview
Semaglutide is a GLP-1 receptor agonist peptide that suppresses appetite, increases satiety, and improves glucose metabolism for pharmaceutical-grade weight loss and blood sugar control, achieving average weight loss of 15-18% body weight (30-40+ pounds) over 6 months in individuals with obesity or diabetes through sustained once-weekly injections or oral dosing. FDA-approved for both type 2 diabetes (as Ozempic) and weight management (as Wegovy), it outperforms all prior GLP-1 agonists including liraglutide with superior efficacy and sustained action.
Clinical advantages include once-weekly dosing convenience, sustained appetite suppression lasting days, improved cardiovascular outcomes in diabetes, renal protection, and metabolic improvements beyond pure weight loss. Users report reduced hunger, increased fullness from smaller portions, improved blood sugar stability, and sustained energy as metabolism optimizes. Gastrointestinal side effects (nausea, constipation) are transient and dose-manageable. For individuals with type 2 diabetes, obesity, or metabolic syndrome seeking pharmaceutical-grade weight loss with cardiovascular and longevity benefits, Semaglutide offers transformation through appetite and glucose regulation.
Studied benefits
- A once-weekly injection that promotes significant weight loss (10–15% on average) and improves blood sugar control
- It also offers proven cardiovascular benefits, reducing the risk of major heart-related events
Reported side effects
- Most common are gastrointestinal issues like nausea and abdominal pain, which typically improve with gradual dose increases
- Rare but serious risks include pancreatitis and gallbladder disease
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Semaglutide (5mg)
Reconstitute with 2.0 mL bacteriostatic water (Final concentration: ~2.5 mg/mL).
Support chronic weight management through GLP-1 receptor activation, leading to reduced appetite and improved metabolic parameters.
Semaglutide (10mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~3.33 mg/mL).
Support chronic weight management through GLP-1 receptor activation and reduced gastric emptying.
Semaglutide (20mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~6.67 mg/mL).
Support chronic weight management and improved metabolic parameters through potent GLP-1 receptor agonism.
| Week | Weekly Dose | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) | 10 units (0.1 mL) | + Log |
| Weeks 5–8 | 500 mcg (0.5 mg) | 20 units (0.2 mL) | + Log |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 40 units (0.4 mL) | + Log |
| Weeks 13–16 | 1700 mcg (1.7 mg) | 68 units (0.68 mL) | + Log |
| Weeks 17+ | 2400 mcg (2.4 mg) | 96 units (0.96 mL) | + Log |
Frequency
Once per week (subcutaneous).
Timing
Consistent day of the week; rotate injection sites.
Cycle length
Long-term management involves titrating to maintenance.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
20 doses of 250 mcg per vial
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein diet to mitigate the risk of muscle loss while this GLP-1 receptor agonist significantly reduces caloric intake through delayed gastric emptying and increased satiety. Incorporate regular resistance training to provide a stimulus for muscle preservation during rapid weight loss. Ensure 7–9 hours of quality sleep to optimize metabolic health and prevent cortisol-driven hunger cues. Maintain optimal hydration and monitor progress through measurements beyond just weight (such as body fat percentage) to ensure the weight loss is primarily coming from adipose tissue rather than lean mass.
Evidence
Research summaries
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Findings: Keeps weight off for over 2 years, shrinks waist, and steadies blood sugar—huge for staying healthy long-haul.
Over 300 adults with extra weight (no diabetes) got weekly Semaglutide shots plus diet tips for 2 years. They lost 15% body weight vs. 2.4% on fake shots! 77% hit 5%+ loss, waist slimmed 14cm, blood pressure dropped. Belly issues were main side (mild), but quit rates low. Unlike quick diets, weight stayed off—no rebound. For teens watching weight, it's proof steady hormone help + habits = real change. Also hints at delaying diabetes by fixing sugar swings early.
Read the study ↗Weight Loss Outcomes and Semaglutide Treatment for Patients With Overweight or Obesity
Findings: Drops pounds fast (5-10% in months), more in non-diabetics, easing joint strain and energy boosts.
Real-world check on 18,000+ patients using Semaglutide like in trials. In 3 months, 1mg dose shed 4%, 2.4mg hit 5%; by 7 months, 7-10%. Non-diabetics lost more (maybe less calorie burn drop). Helps heart by cutting fat weight. Ties to better sugar control via less pee-sugar loss. Imagine carrying less backpack all day—you move easier. Safe for ongoing use, but watch tummy upset at start.
Read the study ↗Long-term weight loss effects of semaglutide in obesity without diabetes (SELECT trial analysis)
Findings: Cuts major heart events 20% while trimming weight, perfect for overweight with heart worries.
Huge trial of 17,000+ overweight adults (no diabetes, but heart history). Semaglutide slashed heart attacks/strokes 20%, plus ~10% weight loss sustained. Not just thin—safer ticker. Blood sugar improved too. For active kids, shows fixing weight early guards heart from sports strains or family history. Mild gut sides, but benefits outweigh.
Read the study ↗Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight
Findings: Stopping regain—keeps loss going vs. ballooning back up on placebo.
After 5 months loss on Semaglutide, half kept it, half switched placebo. Keepers lost another 8%; switchers regained most. 90%+ stayed in study. Proves sticking with it prevents yo-yo. Great life lesson: consistency wins. Waist, sugar, lipids all improved more.
Read the study ↗Identification
Chemistry
- cas
- 910463-68-2 (free base)
- formula
- C₁₈₇H₂₉₁N₄₅O₅₉
- molecular weight
- 4113.64 g/mol (also reported as 4111.1154 exact mass, 4100 Da average)
- sequence
- Modified GLP-1 sequence (31 amino acids, positions 7-37 numbered from full native GLP-1); first 6 N-terminal amino acids of native GLP-1 are missing
- source
- Synthetic; engineered GLP-1 analog derived from natural human GLP-1 hormone
- biosynthesis
- Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS) with post-synthetic acylation
- type
- Linear peptide with N-terminal amino group and C-terminal carboxylic acid; acylated with C-18 fatty acid chain
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks